Bio-Techne

For other uses, see Techne (disambiguation).
Bio-Techne Corporation
Public
Traded as
Industry
  • biotechnology
  • clinical diagnostic
Founded 1976
Founder Dr. Roger C. Lucas
Headquarters Minneapolis, Minnesota, United States
Key people
 Chuck Kummeth (President, CEO)
Products 24,000 products, 14,000 of which are antibodies (2014)
Revenue
  • Increase $452M (2015)
  • Increase $358M (2014)
Number of employees
 >1,000 (2014)
Website Bio-Techne
Footnotes / references
[1][2]

Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014.[2] The company's brands include flagship R&D Systems (Research and Diagnostic Systems Inc.),[3] Boston Biochem, Tocris Bioscience, BiosPacific and Bionostics.[2] The company's products are used in both clinical and research contexts.[4][5] The company was co-founded as a "hematology controls developer"[2] by Dr. Roger C. Lucas, who presently serves as its Chief Scientific Advisor.[6]

Bio-Techne is listed on the NASDAQ under the ticker symbol TECH.[7] Writing for Forbes from an investor's perspective, John Reese praised the management team saying it "...appears to be doing a solid job...",[8] a sentiment echoed by Philip van Doorn, writing for Dow Jones MarketWatch.[9] Interviewing investor Edward B. White for the New York Times, Carole Gould noted that White thought the chief executive, Thomas Oland, was a "deeply committed scientist."[10]

Beginning in 2013, the company's chief executive officer was Chuck Kummeth, who had previously been employed by Thermo Fisher Scientific.[2]

In 2014, the same year it underwent a reorganization and changed its name, the company acquired two companies as part of "an aggressive expansion program" and as "part of a long-term strategy to transform [itself] from a reagent supplier to an applied-markets solution provider."[2] Bio-Techne and the Chinese company PrimeGene (Shanghai PrimeGene Bio-Tech) shared customers and sold complementary products; acquisition of PrimeGene, which was anticipated to have completed by the end of 2014, was a strategic move to provide better integrated product offerings to existing customers and provide for reduced cost of manufacturing for "commodity" products.[2] At the same time, Bio-Techne invested in, with plans to eventually acquire, the American equipment maker CyVek with the intention of adapting CyPlex immunoassay technology toward development of a comprehensive platform for use of Bio-Techne products.[2][11]

Acquisitions

References

  1. ↑ "Form 10-K". EDGAR. U.S. Securities and Exchange Commission. 2015-08-31. p. 34. Retrieved 2016-07-25.
  2. 1 2 3 4 5 6 7 8 9 10 Dutton, Gail (2014-06-15). "Bio-Techne Realigns for Growth". GEN Corporate Profile. Genetic Engineering & Biotechnology News. 34 (12): 10. Retrieved 2016-07-24.
  3. ↑ Murphy, Barbara (1998-05-12). "Amgen Inc. Sells Its Stake in Techne Corp.". Los Angeles Times. Retrieved 2015-04-25. Techne is the parent company for Research and Diagnostic Systems Inc.
  4. ↑ Meguru Miyamoto; Kazuyuki Ishihara & Katsuji Okuda (April 2006). "The Treponema denticola Surface Protease Dentilisin Degrades Interleukin-1β (IL-1β), IL-6, and Tumor Necrosis Factor Alpha". Infection and Immunity. 74 (4): 2462–2467. doi:10.1128/IAI.74.4.2462-2467.2006. PMC 1418930Freely accessible. PMID 16552080.
  5. ↑ C-C Chang; et al. (2012-11-23). "CCN2 inhibits lung cancer metastasis through promoting DAPK-dependent anoikis and inducing EGFR degradation". Cell Death & Differentiation. 20: 443–455. doi:10.1038/cdd.2012.136. Retrieved 2015-04-25.
  6. ↑ "Roger C. Lucas Ph.D.". Executive Profile & Biography. Businessweek. Retrieved 2015-04-25. Dr. Roger C. Lucas, Ph.D. co-founded Techne Corp., in 1985 and serves as its Chief Scientific Advisor.
  7. ↑ "Bio-Techne Corp". Yahoo! Finance. Retrieved 2015-04-25.
  8. ↑ Reese, John P. (2010-10-13). "China Picks Buffett Might Like". Forbes. TECHNE Corporation (TECH). Retrieved 2015-04-25. TECHNE’s management also appears to be doing a solid job
  9. ↑ Doorn, Philip van (2015-03-02). "These are the most profitable Nasdaq biotech companies". Dow Jones MarketWatch. Retrieved 2015-04-25.
  10. ↑ Carole Gould (2000-09-03). "Investing With: Edward B. White". The New York Times. Retrieved 2015-04-25. praising the chief executive, Thomas Oland, as a "deeply committed scientist."
  11. ↑ Kennedy, Patrick (2014-04-05). "Techne Makes Investment in Biotech Test System Firm". Star Tribune. Minneapolis, Minnesota. Retrieved 25 July 2016 – via HighBeam Research. (subscription required (help)).
  12. ↑ "Techne to buy Bionostics for $104m in cash". boston.com. Associated Press. 2013-06-18. Retrieved 2015-04-25. buy Bionostics Holdings Ltd. and its operating subsidiary Bionostics Inc. for $104 million in cash.
  13. ↑ "Bio-Techne Announces Agreement To Acquire Novus Biologicals" (Press release). Bio-Techne. 2014-07-02. Retrieved 2015-04-25 – via PR Newswire.
  14. ↑ "Bio-Techne Announces ProteinSimple Acquisition Completion" (Press release). Bio-Techne. 2014-08-01. Retrieved 2015-04-27.
  15. ↑ "Bio-Techne Corporation Agrees to Acquire Cliniqa Corporation" (Press release). Bio-Techne. 2015-06-05. Retrieved 2016-05-29 – via PR Newswire.
  16. ↑ Staff (2016-03-21). "Bio-Techne Acquires Zephyrus Biosciences". GEN News Highlights. Genetic Engineering & Biotechnology News. Retrieved 2016-07-24.
  17. ↑ Staff (2016-07-21). "Bio-Techne to Acquire Advanced Cell Diagnostics for Up to $325M". GEN News Highlights. Genetic Engineering & Biotechnology News. Retrieved 2016-07-24.

External links

This article is issued from Wikipedia - version of the 11/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.